dactinomycin and su 11248

dactinomycin has been researched along with su 11248 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
El Gendy, MA; El-Kadi, AO; Korashy, HM; Maayah, ZH1

Reviews

1 review(s) available for dactinomycin and su 11248

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

1 other study(ies) available for dactinomycin and su 11248

ArticleYear
Sunitinib, a tyrosine kinase inhibitor, induces cytochrome P450 1A1 gene in human breast cancer MCF7 cells through ligand-independent aryl hydrocarbon receptor activation.
    Archives of toxicology, 2013, Volume: 87, Issue:5

    Topics: Antineoplastic Agents; Breast Neoplasms; Cytochrome P-450 CYP1A1; Dactinomycin; Dose-Response Relationship, Drug; Enzyme Induction; Enzyme Inhibitors; Female; Gene Expression Regulation, Enzymologic; Humans; Indoles; Ligands; MCF-7 Cells; Protein-Tyrosine Kinases; Pyrroles; Receptors, Aryl Hydrocarbon; Resveratrol; RNA, Messenger; Stilbenes; Sunitinib; Transcriptional Activation

2013